The case for & against
Bull & Bear analysis
Bearish
Dentsply Sirona Inc. (NASDAQ:XRAY) is a dominant player in the dental products sector, focused on innovative dental technologies and comprehensive supplies, including equipment, instruments, and consumables. As a leader in restorative dentistry and digital dentistry, the company operates in a highly competitive environment characterized by ongoing technological advancements and procedural changes. Dentsply is currently navigating a transformative phase, aiming to return to growth through its strategic Return to Growth Action Plan, which emphasizes innovation and enhanced customer engagement.
Bull says
- ↑Q1 revenue $880M vs. $842M consensus; 2026 guidance at $3.5–3.6B
- ↑R&D spend increasing under Return to Growth plan to drive new products
- ↑Q1 operating cash flow of $40M, up from $7M YoY via working-capital gains
- ↑Adjusted EBITDA margin rose to 19%, up 220bps YoY, reflecting cost discipline
- ↑$128M dividend savings allocable to debt paydown or share repurchases
- ↑High earnings yield, strong book-to-price and healthy liquidity metrics
Bear says
- ↓Adjusted EBITDA margin fell 430bps YoY amid volume and mix challenges
- ↓Organic sales likely to decline; 2026 EPS guide at $1.40–$1.50 suggests flat growth
- ↓$80M annual tariff hit adds pressure on operational profitability
- ↓Lower-cost competitors eroding share in restorative and digital dentistry
- ↓Weak momentum and price resistance hinder revenue and margin recovery
- ↓Analyst downgrades reflect waning confidence in growth and profitability
Investment themes with XRAY
Medical Devices↑ +0.44%
Devices and instruments for medical treatment
MEDP · RDNT · OPCH
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-09-2026neutral
Transcript signals
Bull points
- Q1 marked the start of executing the Densply Serona Return to Growth Action Plan. Our results reflect a business-in transition and do not yet capture the actions underway intended to drive sustained profitable growth.
- These actions are already gaining momentum and are expected to contribute more meaningfully as the year progresses.
- We're also seeing early encouraging traction with our distribution partners and I'll share more detail on that shortly.
Bear points
- sales declined 6.7%
- were down 4.5%
- Adjusted EBITDA margins declined 430 basis points
Read full transcript analysis ›